Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM).

@article{Bloss2004PemetrexedAO,
  title={Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM).},
  author={Jeffrey D. Bloss and Antoinette J. Wozniak and Pasi Antero Janne and Chandra Prakash Belani and Mary Louise Keohan and H. Ross and Jonathan A. Polikoff and David T. Mintzer and Leslie P. Bloss and Coleman K. Obasaju},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={7198}
}
7198 Background: The improved efficacy of pemetrexed (ALIMTA, Eli Lilly and Co) in combination with cisplatin versus cisplatin alone, in a phase 3 trial of patients with malignant pleural mesothelioma, has led to a demand for patient access to pemetrexed prior to regulatory approval. An Eli Lilly and Co EAP was opened to allow access to all eligible patients with MM. This non-randomized study was designed to gather additional efficacy and safety data on pemetrexed alone and in combination with… CONTINUE READING
BETA